Technical Analysis for GLSI - Greenwich LifeSciences, Inc.

Grade Last Price % Change Price Change
F 13.44 -0.07% -0.01
GLSI closed down 0.07 percent on Friday, November 1, 2024, on 27 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Earnings Movers Other 0.00%
Fell Below 20 DMA Bearish -0.07%
Fell Below 200 DMA Bearish -0.07%
Fell Below 50 DMA Bearish -0.07%
Bollinger Band Squeeze Range Contraction -0.07%
Death Cross Bearish -6.60%
200 DMA Support Bullish -6.60%

   Recent Intraday Alerts

Alert Time
Up 1% about 19 hours ago
Possible NR7 about 19 hours ago
Possible Inside Day about 19 hours ago
Fell Below 10 DMA 2 days ago
20 DMA Support 2 days ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Greenwich LifeSciences, Inc. Description

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Acid Immunotherapy Surgery Cancer Treatment Breast Cancer Clinical Trial Treatment Of Breast Cancer Her2 Cancer Center Her2/Neu

Is GLSI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.44
52 Week Low 8.0
Average Volume 29,132
200-Day Moving Average 14.14
50-Day Moving Average 14.06
20-Day Moving Average 13.68
10-Day Moving Average 13.72
Average True Range 0.64
RSI (14) 45.05
ADX 9.97
+DI 20.88
-DI 21.72
Chandelier Exit (Long, 3 ATRs) 12.86
Chandelier Exit (Short, 3 ATRs) 14.45
Upper Bollinger Bands 14.44
Lower Bollinger Band 12.93
Percent B (%b) 0.34
BandWidth 11.01
MACD Line -0.09
MACD Signal Line -0.11
MACD Histogram 0.0178
Fundamentals Value
Market Cap 172.68 Million
Num Shares 12.8 Million
EPS -0.70
Price-to-Earnings (P/E) Ratio -19.20
Price-to-Sales 0.00
Price-to-Book 12.31
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.85
Resistance 3 (R3) 13.87 13.75 13.78
Resistance 2 (R2) 13.75 13.65 13.74 13.76
Resistance 1 (R1) 13.60 13.58 13.54 13.58 13.74
Pivot Point 13.48 13.48 13.45 13.47 13.48
Support 1 (S1) 13.32 13.37 13.26 13.30 13.14
Support 2 (S2) 13.20 13.31 13.19 13.12
Support 3 (S3) 13.05 13.20 13.10
Support 4 (S4) 13.03